CA
GSK icon

Continuum Advisory’s GSK GSK Stock Holding History

Continuum Advisory’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,671
Closed -$245K – 463
2025
Q3 		$245K Sell
5,671
-1,285
-18% -$50.2K 0.03% 391
2025
Q2 		$267K Sell
6,956
-4,973
-42% -$190K 0.03% 359
2025
Q1 		$462K Sell
11,929
-151
-1% -$5.53K 0.06% 243
2024
Q4 		$409K Buy
12,080
+1,481
+14% +$53.3K 0.05% 272
2024
Q3 		$365K Buy
10,599
+487
+5% +$19.9K 0.05% 296
2024
Q2 		$389K Buy
10,112
+52
+0.5% +$2.19K 0.06% 262
2024
Q1 		$449K Sell
10,060
-6,925
-41% -$286K 0.07% 246
2023
Q4 		$630K Buy
16,985
+3,094
+22% +$111K 0.09% 248
2023
Q3 		$504K Buy
+13,891
New +$493K 0.08% 273

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Continuum Advisory's GSK Position: Q4 2025 in Review

Continuum Advisory sold out of GSK (GSK) in Q4 2025, closing a stake of 5,671 shares — an estimated $245K sold.

Continuum Advisory first reported a position in GSK in Q3 2023 and held it in 9 quarters. The position peaked at $630K in Q4 2023. 996 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

  • Continuum Advisory reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
  • Continuum Advisory sold 5,671 GSK shares in Q4 2025, an estimated $245K.
  • Continuum Advisory first reported a position in GSK in Q3 2023 and held it in 9 quarters.
  • Continuum Advisory's GSK position peaked at $630K in Q4 2023.
  • 996 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Continuum Advisory's 13F filing for Q4 2025, filed 11 Feb 2026.